<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000119312523068406/d409752d8k.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000119312523068406/0001193125-23-068406-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Acadia Pharmaceuticals Inc

Announcement: ACAD 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000095017023004757/acad-20221231.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000095017023004757/0000950170-23-004757-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

ACADIA PHARMACEUTICALS: Trofinetide NDA filed & pimavanserin in Phase 3
Current Analysis:
ACADIA's NUPLAZID® is FDA-approved to treat Parkinson’s disease psychosis. They've submitted to the FDA an NDA for trofinetide for the treatment of Rett syndrome with PDUFA target action on March 12, 2023. Another drug in the pipeline is pimavanserin evaluated in a Phase 3 clinical program for negative symptoms of schizophrenia. ACADIA also announced their internally discovered new molecule, ACP-204, which is currently evaluated in a Phase 1 clinical program.

Forward-Looking Analysis:
ACADIA's NUPLAZID® has a first mover advantage in the US. However, they'll face increasing competition from other antipsychotic therapies. Trofinetide and pimavanserin, if approved, have the potential to create new revenue streams for the company. ACADIA's leveraging strategic R&D partnerships with Stoke to meet their long-term growth objectives. In addition, COVID-19 has disrupted supply chains and clinical trials, and may negatively impact retail investors' short-term prospects.

Announcement: ACAD 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/acad-20230227.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 2.02 Item 9.01

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/80255/000008025523002572/acad13gadec22.txt>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000008025523002572/0000080255-23-002572-index.htm>Original filing index</a>
                    </div>

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ACAD SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/102909/000110465923015189/tv0151-acadiapharmaceuticals.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000110465923015189/0001104659-23-015189-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/315066/000031506623001363/filing.txt>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1070494/000031506623001363/0000315066-23-001363-index.htm>Original filing index</a>
                    </div>